<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03491410</url>
  </required_header>
  <id_info>
    <org_study_id>CHLOBREASTASP</org_study_id>
    <nct_id>NCT03491410</nct_id>
  </id_info>
  <brief_title>Breast Cancer Active Surveillance, Alternative Option, Aspirin Included</brief_title>
  <official_title>Breast Cancer Active Surveillance Alternative Option, Can Aspirin Make the Difference?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar Lisboa Ocidental</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Hospitalar Lisboa Ocidental</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental, clinical, and epidemiological studies have all demonstrated the strong
      association between chronic inflammation and cancer, and many studies have correlated the
      prolonged presence of the inflammatory milieu with an increased risk for developing
      cancer.(1) Although the potential mechanism for aspirin preventing breast cancer is not
      known, possible pathways may involve platelets, inflammation, cyclooxygenase (COX) 2,
      hormones, or PI3 kinase. (2).

      In actual clinical practice there exist clear guidelines for the use of aspirin in colorectal
      cancer but no such guidelines exist for the use of aspirin in breast cancer patients.

      In the Unit´s proper experience, in patients under active surveillance and metastatic ones
      some present very good responses both in the neoadjuvant and in the metastatic setting but
      investigators intend to provide evidence and not just the experience. This study patients are
      proposed to combine their standard treatment with aspirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer patients with diagnosis of Ductal or Lobular Invasive Carcinoma or CDis that
      refuse to underwent surgery or are not qualified for, and independently of age or of their
      actual staging, are going to be allocated, randomly and in double masked way to one of two
      arms:

      Arm 1: standard Unit´s protocol + placebo Arm 2: standard Unit´s protocol + aspirin
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Patients Overall survival in arm 2 superior to the arm 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metastatic Disease Stability</measure>
    <time_frame>1 year</time_frame>
    <description>Metastatic disease stability (non progression) determined by imaging (ecography, CT,PET-CT or Bone Scintigraphy) in arm 2 superior to the arm 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response till patient decides to exit the active surveillance</measure>
    <time_frame>6 months</time_frame>
    <description>Tumor response till patient decides to exit the active surveillance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 1: standard Unit´s protocol + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2: standard Unit´s protocol + aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Low Dose</intervention_name>
    <description>Low-Dose Aspirin is to be added in the standard patient´s treatment</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo is to be added in the standard patient´s treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Every adult (above 18) y.o.patient with histologic diagnosis of Breast Cancer that refuse
        or is not suitable for surgical treatment, or with metastatic disease, remaining this way
        in an &quot;active surveillance&quot;

        Exclusion Criteria:

        Allergy or toxicity to aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zacharoula Sidiropoulou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar Lisboa Ocidental</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vasco Fonseca, MD</last_name>
    <phone>210 431 704/18</phone>
    <email>medicinavf@yahoo.com</email>
  </overall_contact>
  <reference>
    <citation>Chen WY, Holmes MD. Role of Aspirin in Breast Cancer Survival. Curr Oncol Rep. 2017 Jul;19(7):48. doi: 10.1007/s11912-017-0605-6. Review.</citation>
    <PMID>28597105</PMID>
  </reference>
  <results_reference>
    <citation>Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des. 2009;15(17):1949-55. Review.</citation>
    <PMID>19519435</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>April 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2018</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Hospitalar Lisboa Ocidental</investigator_affiliation>
    <investigator_full_name>Zacharoula Sidiropoulou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Active Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

